Publications by authors named "A Potron"
Background: Meropenem-vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an effective inhibitor of KPC enzymes in vitro. This study aimed to describe the initial uses and efficacy of MEM-VAB for compassionate treatment during the first 21 months following its early access in France.
Method: A national multicenter retrospective study was conducted, including all patients who received at least one dose of MEM-VAB between 20 July 2020, and 5 April 2022.
Article Synopsis
- Carbapenem-resistant Acinetobacter baumannii (CRAB) is a major global health concern, particularly in bloodstream infections, making early detection vital for effective treatment.
- The RESIST ACINETO immunochromatographic assay accurately detects key carbapenemases (OXA-23, OXA-40/58, NDM) in clinical isolates, demonstrating perfect sensitivity and specificity in both bacterial and blood cultures.
- Utilizing RESIST ACINETO can enhance rapid identification of CRAB in high-incidence regions like the Balkans and Southeast Asia, facilitating optimized treatment strategies, especially with alternatives like cefiderocol.
Cross-transmission of Acinetobacter junii carrying blaOXA-58 in a neonatal ICU.
J Antimicrob Chemother
August 2024
Background: Nasal colonization of two preterm infants in our neonatal ICU by Acinetobacter junii carrying the blaOXA-58 carbapenem resistance gene was demonstrated.
Objectives: To study whether the two isolates were identical and to investigate the hypotheses of cross-transmission.
Methods: Antibiotic susceptibility tests of the two isolates were performed by standard diffusion and the MICs of carbapenems determined by the MIC-gradient strip method.
Article Synopsis
- * This review assesses the evidence for using cefiderocol to treat severe pneumonia caused by CRAB, analyzing studies and trials from 2017 to 2023, while highlighting the complexities in treatment outcomes.
- * There are conflicting results regarding cefiderocol’s effectiveness, with some studies showing higher mortality rates compared to other treatments, indicating that optimized dosing or combination therapies may be necessary to improve patient outcomes.
Article Synopsis
- The study investigates the effectiveness of cefiderocol, an alternative drug for treating carbapenem-resistant Acinetobacter baumannii (CRAB) infections, particularly in a critically ill patient.
- The case presented shows initial treatment failure with colistin and tigecycline, but subsequent treatment with colistin and cefiderocol resulted in significant clinical improvement.
- The research highlights that adaptive resistance to cefiderocol (ARC) was noted in certain CRAB isolates, suggesting that cefiderocol may not be effective as a monotherapy for specific types of CRAB infections, warranting careful consideration of treatment options based on the strains present.